Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease.
Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis.
Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.
Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.
Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses.
In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.
Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
Differential immunodetection of toxin B from highly virulent Clostridium difficile BI/NAP-1/027.
Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in Stool.
Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.
Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-?B Activity.
Comparison of Clostridioides difficile Stool Toxin Concentrations in Adults With Symptomatic Infection and Asymptomatic Carriage Using an Ultrasensitive Quantitative Immunoassay.
Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis.
Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.
Toxin A-Predominant Pathogenic Clostridioides difficile: A Novel Clinical Phenotype.
Therapeutic Mechanism of Macrophage Inflammatory Protein 1 a Neutralizing Antibody (CCL3) in Clostridium difficile Infection in Mice.
Clostridioides difficile Toxin A Remodels Membranes and Mediates DNA Entry Into Cells to Activate Toll-Like Receptor 9 Signaling.
Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum.